Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y, Hata N, Takigawa K, Arita H, Kuga D, Hatae R, Sangatsuda Y, Fujioka Y, Sako A, Umehara T, Yoshitake T, Togao O, Hiwatashi A, Yoshimoto K, Iwaki T, Mizoguchi M.
Funakoshi Y, et al. Among authors: takigawa k.
Cancer Med. 2021 May;10(10):3177-3187. doi: 10.1002/cam4.3860. Epub 2021 Apr 10.
Cancer Med. 2021.
PMID: 33838014
Free PMC article.